Abstract

Merck & Co. will pay Eisai $750 million plus milestone payments of up to $4 billion to jointly develop Eisai’s lenvatinib mesylate, a small-molecule tyrosine kinase inhibitor already approved to treat certain cancers. The two firms will develop the drug, sold as Lenvima, as a monotherapy and in combination with Merck’s Keytruda anti-PD-1 cancer therapy. “There is strong scientific evidence supporting synergistic effects of Keytruda when used in combination with Lenvima,” says Roger M. Perlmutter, president of Merck Research Laboratories.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call